Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nyse MKT  >  CEL-SCI Corporation    

 SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2015 0,35 M
EBIT 2015 -41,2 M
Net income 2015 -
Debt 2015 -
Yield 2015 -
Sales 2016 0,60 M
EBIT 2016 -43,4 M
Net income 2016 -35,9 M
Debt 2016 -
Yield 2016 -
PER 2015 -
PER 2016
Capi. / Sales 2015 202x
Capi. / Sales 2016 118x
Capitalization 70,5 M
More Financials
Company
CEL-SCI Corp. is a biotechnology company, which is involved in the research and development of investigational immunotherapy products for the treatment of cancer and infectious diseases.The company's lead investigational therapy, Multikine, is being developed as a potential therapeutic agent... 
More about the company
Latest news on CEL-SCI CORPORATION
07/29 CEL SCI : Expands Its Phase I Study for Treatment of Anal Warts in HIV/HPV Co-In..
07/29 CEL SCI : SEC Receives Insider Trading Form Involving CEL-SCI
07/29 CEL SCI : Biotechnology Stocks Review -- Juno Therapeutics, Amicus Therapeutics,..
07/28 CEL-SCI CORPORATION : HIV/HPV Guru Comes on Board to Battle Cancer, Driving CEL-..
07/20 CEL SCI : Expands Its Phase I Study for Treatment of Anal Warts in HIV/HPV Co-In..
07/12 CEL SCI : Updates on June Patient Enrollment in Its Phase 3 Head and Neck Cancer..
07/08 CEL SCI : Reports June Patient Enrollment in Its Phase 3 Head and Neck Cancer Tr..
07/06 CEL SCI : Updates on June Patient Enrollment in Its Phase 3 Head and Neck Cancer..
More news
Sector news : Bio Therapeutic Drugs
07/31 QUINTILES TRANSNATIONAL : Announces Pricing of Secondary Public Offering
07/30 SEATTLE GENETICS : reports 2Q loss
07/30 QUINTILES TRANSNATIONAL : Announces Launch of Secondary Public Offering of Commo..
More sector news : Bio Therapeutic Drugs
Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions